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Pain is essential for avoidance of tissue damage and for promotion of healing. 
Notwithstanding the survival value, pain brings about emotional suffering reflected 
in fear and anxiety, which in turn augment pain thus giving rise to a self-sustaining 
feedforward loop. Given such reciprocal relationships, the present article uses neuro-
scientific conceptualizations of fear and anxiety as a theoretical framework for hitherto 
insufficiently understood pathophysiological mechanisms underlying chronic pain. To 
that end, searches of PubMed-indexed journals were performed using the following 
Medical Subject Headings’ terms: pain and nociception plus amygdala, anxiety, cog-
nitive, fear, sensory, and unconscious. Recursive sets of scientific and clinical evidence 
extracted from this literature review were summarized within the following key areas: 
(1) parallelism between acute pain and fear and between chronic pain and anxiety; 
(2) all are related to the evasion of sensory-perceived threats and are subserved by sub-
cortical circuits mediating automatic threat-induced physiologic responses and defensive 
actions in conjunction with higher order corticolimbic networks (e.g., thalamocortical, 
thalamo-striato-cortical and amygdalo-cortical) generating conscious representations 
and valuation-based adaptive behaviors; (3) some instances of chronic pain and anxiety 
conditions are driven by the failure to diminish or block respective nociceptive information 
or unconscious treats from reaching conscious awareness; and (4) the neural correlates of 
pain-related conscious states and cognitions may become autonomous (i.e., dissociated) 
from the subcortical activity/function leading to the eventual chronicity. Identifying relative 
contributions of the diverse neuroanatomical sources, thus, offers prospects for the devel-
opment of novel preventive, diagnostic, and therapeutic strategies in chronic pain patients.
Keywords: amygdala, cognitive, fear, nociception, sensory, unconscious
iNTRODUCTiON
Acute pain is essential for survival by avoidance of tissue damage and by promotion of healing. This 
is not so for chronic (i.e., lasting more than 3 months) pain (1) that has no beneficial value (2). By 
afflicting over 100 million Americans and costing about $635 billion, chronic pain continues to be 
a challenge of pandemic enormity for patients, for their families, for medical establishment, and 
for society as a whole (3). What causes otherwise healthy people to develop pain-related disability, 
to withdraw from their regular activities, and to cultivate attitudes filled with gloomy perspectives, 
complaining, misery, and suffering (4)?
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An autobiographic book by Ruben Gallego entitled “White 
on Black” (5) describing the life of a patient afflicted with severe 
cerebral palsy may provide some insights into these conundrums. 
Notwithstanding the excruciating pain intensity (6) and the per-
ception of blatant indifference from the nursing staff, the author 
only mentions “pain” twice throughout the entire text. In one 
instance, he routinely rolls out of bed to fall onto the floor in order 
to crawl to the bathroom. In the second instance, pain is likewise 
devoid of any fear or anxiety and is rather perceived as “senseless.” 
The author eventually graduates from a technical college, marries 
thrice and fathers three children. He figures out ways of refusal to 
accept fear and anxiety. Not so for chronic pain patients. They tend 
to catastrophize in conjunction with experiencing overwhelming 
anxiety about the ongoing and future pain episodes (7–9).
Chronic pain is indeed a complex phenomenon engaging, in 
addition to sensory systems, extensive threat response neuro-
circuitry with emotional and cognitive constituents merging on 
the brain networks comprising the nucleus accumbens (NAc), 
the amygdala, the extended amygdala, and the medial prefrontal 
cortex (mPFC). Assuming neurobiological overlap between the 
processing of pain and of other threatening signals the present 
article focuses on the components of pain that are related to fear 
and to anxiety and are germane for comorbidity of these condi-
tions and for transition from acute to chronic pain (10).
At the outset of this review, we compare epidemiological 
and clinical data on pain and fear/anxiety comorbidity and this 
contrast serves as the foundation for the premise of a neurobio-
logical similitude between these commonly comorbid conditions. 
We then discuss possible pain mechanisms as they relate to the 
mediation of fear and anxiety. Next, we depict specific evidence 
for testable hypotheses on mechanistically informed psycho-
therapeutic and -pharmacological interventions. Finally, sum-
mary and conclusions are presented.
BiBLiOGRAPHiC SeARCH
Preclinical and clinical English language peer reviewed literature 
search on anxiety and fear in pain along with the mechanisms 
of normative threat processing and their potential impairments 
in patients with chronic pain disorders was undertaken using 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) from inception 
until December 2017. Medical Subject Headings’ terms used 
included pain and nociception plus amygdala, anxiety, cognitive, 
fear, sensory, and unconscious. Information on the mechanisms 
and neurobiology of pain, fear, anxiety, cognition, analgesia, and 
salience were also drawn from recent seminal reviews of these 
topics (11–15). The scopes of the review were adjusted based on 
consultations with scientists and clinicians, manual searches for 
relevant articles from the selected papers’ reference lists along 
with the utilization of PubMed’s “similar articles” function.
KeY TeRMS
Nociception and Pain
Noxious (mechanical, thermal, or chemical) stimuli activate C and 
A delta fibers. Nociception involves neurophysiologic mechanisms, 
including afferent activation in neural pathways responsible for 
detection or reflexive response to noxious stimuli. Like fear (see 
below), the response to an acute nociceptive stimulus includes 
pallor, freezing, tremulousness, diaphoresis, tachycardia, 
hypertension, and preponderance of the adrenomedullary, as 
compared to the noradrenergic stimulation (16, 17). The latter 
may be an adaptive reaction as epinephrine promotes memory 
consolidation (18) and improves coping with extreme situations 
by enhancing “gating” (i.e., activating descending modulatory 
systems) of noxious stimuli from reaching conscious awareness 
(1). Consequently, to assert prompt and automatic responses to 
hazardous situations, substantial nociceptive components remain 
sub- or unconscious (12).
Pain is experienced when the modulatory gating threshold is 
surpassed; so in acute situations, the attention is drawn to the 
bodily effects of the noxious stimuli. Chronic pain, by contrast, 
may occur in the absence of obvious tissue injury. Whatever the 
cause may be, pain is an unpleasant (1) or distressing (19) state 
associated with actual or potential tissue damage and comprised 
of sensory, emotional, cognitive, and social components (19, 
20). Hence is the complex interplay among nociceptive percep-
tions and accompanying cognitive, behavioral, and emotional 
phenomena (13) so that pain experiences, derived from biologi-
cal factors (e.g., genetic make-up, concentrations of endorphins 
and catecholamines, age, sex, underlying medical conditions 
and neuropsychopathology) are modulated by psychosocial 
variables (e.g., cultural, societal, and familial milieu in conjunc-
tion with upbringing; individual expectations; educational and 
professional backgrounds; and memories of prior pain epi-
sodes). In fact, the division between sensory and psychosocial 
pain expressions is not that perceptible (21) so co-occurring 
fear and anxiety not only contribute to the cognitive/behavioral 
pain aspects (22) but also worsen sensory phenomena (23).
Fear and Anxiety
Fear is defined as a fundamental emotion promptly arising in 
the context of tangible and actual threats. It may be appropri-
ate when reality-based and amenable to cognitive control, but 
is deemed to be a phobia (e.g., pain phobia or agliophobia) if 
becomes irrational (24). The emotional disturbance evoked by 
various threats is only part of the homeostatic regulation, with 
epinephrine secretion predominating that of norepinephrine 
in conjunction with the pallor, freezing, diaphoresis, tachy-
cardia, hypertension, and shaking (17). Anxiety refers to a 
related yet distinct concept encompassing an uncertain source 
of threat (such as in chronic pain) or future-oriented cogni-
tions linking fear and similar emotions to personal meaning 
of events and of actions (25, 26). Short-term anxiety states 
may be appropriate and adaptive whereas long-term ongoing 
anxiety periods are usually consistent with anxiety disorders 
(27). See Table  1 for comparison of acute and chronic pain 
with fear and anxiety.
Conscious and Unconscious Processing
An attempt to integrate elements from psychological formula-
tions of fear and anxiety symptoms into a neurobiological 
entity faces a major question: how to define “unconscious” 
as it relates to brain processes that do not produce conscious 
TABLe 1 | Key Characteristics of Pain, Fear and Anxiety.
Threat
Clear Uncertain
Symptom (or 
intervening 
variable)
Fear Acute pain Anxiety Chronic pain
Survival value Avoidance of danger or injury None
Sensory input Sensory overload: hearing, taste, 
sight, smell, and touch
Nociceptive overload May be devoid of sensory or nociceptive input
Unconscious 
component
Conditioned cues Nociception Libidinal drives Irresistible drives to seek and consume 
analgesic drugs
Conscious 
component
Dread of loss of control and of 
dying
Distress and other negative 
affective states
Excessive worry and intrusive 
thoughts or memories
Unwarranted worry about an impending 
analgesic dose reduction and catastrophizing
Behavior Avoidance, facial expressions, 
freezing, and escape
Escape from harmful agents 
or deterrence of motion to 
advance healing
Restlessness, fidgeting, and 
irritability
Pain behavior: facial expressions, stereotypic 
actions, complaining, and absenteeism; using 
pain as proxy for gaining pity, appreciation, 
or exemption from routing chores and 
responsibilities
Neuroanatomy Lateral amygdala, CeA, NAc, BA NAc, amygdala, cingulate, 
and insular cortices along 
with brain stem nuclei e.g., 
PAG
Amygdala and extended amygdala, including the BNST
Neurochemistry Sympathetic arousal: epinephrine>>norepinephrine Allostatic load in the form of CRF, glutamate, norepinephrine and 
glucocorticoids
Autonomic 
responses
Pallor, freezing, diaphoresis, tachycardia, hypertension, and 
shaking
 ↓ heart rate variability
Typical conditions Panic disorder Mechanical, thermal, 
chemical, ischemic or 
inflammatory injury
Generalized anxiety disorder Negative affective states: hyperkatifeia, 
neuropathic pain, excessive responses to 
painful (hyperalgesia) or even normally non-
painful (allodynia) stimuli
BA, basal nucleus; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; CRF, corticotropin-releasing factor; NAc, nucleus accumbens; PAG, 
periaqueductal gray matter.
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percepts. “Unconscious” is a somewhat clichéd entity given 
multiple definitions ranging Freudian Topographic Model, e.g., 
dreams, parapraxes, traumatic, and painful memories (28) to 
universal archetypal images by Jung (29), and the System One 
fast and intuitive thinking processes in Kahneman and Tversky’s 
Prospect Theory (30).
“Unconscious” may be defined from the cognitive, emo-
tional, neurological, psychopathological, pharmacological, 
and legal perspectives (among other things). We address 
unconscious processing in conditions such as pain, anxiety and 
fear (31, 32) from the neurobiological standpoint. Specifically, 
we will consider high-amplitude low-frequency endogenous 
excitation of the limbic system normatively subordinated to the 
cortical default mode network containment as a valid version 
of “unconscious” (12, 15, 33–35). Although only one of many 
acceptable ways that “unconscious” might be conceptualized, 
this approach’s advantages include: (a) clearly defined neuro-
anatomical and electrophysiological criteria (33); (b) a firm 
foundation of cognitive neuroscience establishing links to the 
related memory and attention networks research foundation 
(36), and (c) its relationship to neuropsychopathology has been 
extensively accepted (33, 37).
PAiN AND FeAR/ANXieTY: 
ePiDeMiOLOGiCAL AND CLiNiCAL LiNKS
Numerous epidemiological surveys suggest that anxiety disor-
ders are particularly prevalent in pain patients (11, 38, 39) and 
are associated with worsened functional outcomes (7). The most 
comprehensive of these studies, the US National Comorbidity 
Survey Part II, found the odds ratio of 4.27 for the association 
between chronic arthritic pain and anxiety disorders (40). Similar 
figures were reported for other patients with arthritis and for those 
with migraine, back pain (41), spinal pain (42), fibromyalgia (43), 
and the complex regional pain syndrome (44). Such findings are 
consistent with the international chronic pain and anxiety data 
from 17 countries (n = 85,088) in various parts of the world (45).
The mechanisms of the above links are likely to be bidi-
rectional (46) and to involve environmental, psychosocial, 
and neurobiological causes (47). Four potential categories of 
interaction may (co)exist between pain and fear/anxiety (11), 
including: (1) causality; (2) mutual influence; (3) common 
predisposing factor; or (4) independence (i.e., no interaction). 
Accordingly, anxiety accompanied by depression (48) and by 
other negative affective and cognitive states (49) may be a direct 
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cause for emotional pain, that is to say psychache (50) and/
or to produce pain via excessive muscle contraction as well as 
via endocrine or other stress-induced pathophysiological end 
organ alterations (51, 52).
“Mutual maintenance” (i.e., influence) appears to be the most 
notable interaction. That is why, pain commonly (53, 54) arising 
in the context of abuse and violence (11) can become a condi-
tioned stimulus eliciting fear and anxiety that in turn enhance 
subjective pain experience (55, 56) with concurrent avoidance of 
both pain- and fear-related situations and ensuing deterioration 
of both conditions (46, 50). In a course of pain and fear/anxiety 
sensitization, cross-sensitization might likewise occur. If that is 
the case, pain episodes could increase susceptibility to the devel-
opment of fear and anxiety syndromes (or even trigger relapse) 
and vice versa. In view of that, “pre-pain” state may turn into a 
bona fide pain state as increased fear or anxiety serves as a tip-
ping point disrupting the equilibrium. This is observed in acute 
exacerbations of pain by anxiety in healthy subjects (57) and by 
tempering anxiety with drugs (e.g., gabapentin) that have both 
anxiolytic (55, 58, 59) and analgesic (60) properties. Serotonergic 
impairments (61) may be a common predisposing factor. Another 
predisposing factor is a chronic or excessive use of opioid analge-
sics that amplify pain [viz., opioid-induced hyperalgesia and/or 
pain chronification (61)] on top of evocation of anxiety, fear, and 
of other negative affective states (62, 63).
Aside from the clinical impression, including the vignette in 
the Introduction Section (5), no studies to date have examined 
outcomes of pain conditions that are devoid (i.e., independent) 
from fear and anxiety. On the other hand, due to recurring stress 
accompanied by hopelessness, catastrophizing (57), horror (64), 
or avoidance of pain-related situations (11, 65), chronic pain may 
be viewed as a version of post-traumatic stress disorder (PTSD) 
(65, 66). Since the lack of peritraumatic fear and horror confers 
resilience to the development of post-traumatic symptomatology 
(DSM-IV-TR) (67, 68), it may also be plausible to find paucity 
of chronic pain cases in the absence fear and anxiety responses. 
Consistent with this assumption, timely and adequate peritrau-
matic analgesia may prevent the development of fear learning 
in both laboratory animals (69) and in humans (70). In short, 
understanding neurobiology of pain as it may relate to that of 
anxiety/fear could further support the former’s inclusion within 
the disorders of the threat response system (65, 71).
PAiN AND FeAR: CLiNiCAL 
PReSeNTATiON AND  
HOMeOSTATiC ROLe
Pain may indeed be considered within the spectrum of the fear/
anxiety disorders, which is encoded in the “persistently high level 
of anxiety” criterion of the Diagnostic and Statistical Manual 
of Mental Disorders, 5th Edition (27) diagnostic category for 
Somatic Symptom Disorder with Predominant Pain in consort 
with “chest pain” and “muscle aches or soreness” respective 
criteria of panic- and generalized anxiety disorders. While no 
clinical studies specifically link the neural bases of pain and fear/
anxiety, multiple lines of evidence suggest that pain is embedded 
within extensive threat response circuitry (72) that is critical for 
the survival of individuals and species via the evasion of real and/ 
or perceived hazards. Thus, both pain and fear may be considered 
as intervening variables connecting threatening stimuli and con-
sequent pathophysiological alterations with behaviors aimed at 
regaining the homeostatic equilibrium (73).
In chronic pain, tissue injury and other threats are not 
directly related to the above changes but are rather modulated 
by biopsychosocial variables as well as changes in brain plastic-
ity that may alter an individual’s responsivity. Explicitly, while 
pain and fear/anxiety symptomatology are derived from pre-
cipitating factors, their clinical manifestations may be shaped 
by psychosocial setting, pre-existing neuropsychopathology 
and prior exposure to the same type of stimuli (see section Key 
Terms). Moreover, responses to various threats may be inter-
related, be they sensory, visual, or interoceptive (72), which is 
critical for coordination, prioritizing, and selecting the most 
advantageous choices (74).
ACUTe/CHRONiC PAiN vs. FeAR/
ANXieTY: CiRCUiTS AND FUNCTiONS
Responses to goal-objects comprise diverse informational features 
of the stimuli, events, or internal states. These features include 
but not limited to rate, incidence, proximity, timing, and quantity 
of the stimuli (44, 75). Evaluation of these informational features 
is critical for higher level cognitive and valuational processing 
with consequent behavioral choices. Multiple brain regions are 
involved in the assessment of informational features, their valua-
tion, and probability estimates.
Sensory inputs concerning threats are relayed to the lateral 
amygdala and are subsequently conveyed from there to the 
central nucleus (CeA) and to the NAc after passing through the 
basal nucleus (BA) for generation of fear-related physiological 
(e.g., autonomic nervous system), emotional, and behavioral 
(e.g., freezing, escape, fight, and avoidance) responses. The CeA’s 
laterocapsular division (namely, the nociceptive amygdala) is 
involved in the descending pain modulation system (i.e., gating) 
determining pain-related affect, motivations, and behaviors by 
integrating nociception with interoceptive and environmental 
information with higher order cognitive percepts of objectives, 
their valuation, and context (76–78).
Fear dulls acute pain, which may be advantageous from a 
phylogenetic standpoint by promoting fight-or-flight operations; 
anxiety conversely worsens pain experience (79). In terms of 
neuroanatomy, fear vs. anxiety are differentiated by the engage-
ment of the of the extended amygdala structure, the bed nucleus 
of the stria terminalis (BNST) (15) in the latter (but not in the 
former) perhaps by reason of inadequate extinction (80–82) and/
or due to top-down suppression by the hippocampus (56) and by 
the mPFC (80, 83). In the bottom-up fashion fear- and anxiety-
related subcortical limbic structures indirectly (15) affect lateral, 
medial, and insular cortices to contribute to respective conscious 
experiences (14).
Acute pain (84, 85) and fear (86, 87) are associated with phasic 
homeostatic responses to proximal and tangible threats. Chronic 
pain (88) and anxiety (15), in contrast, are of tonic and allo-
static (89) nature with similar to each other autonomic changes 
FiGURe 1 | Schematic overview of the neurobiological processes underlying evolution of chronic pain and anxiety disorders. Sensory inputs concerning threats are 
relayed to the amygdala and other limbic structures, e.g., the central nucleus, the nucleus accumbens, the basal nucleus for generation of fear- or acute pain-related 
physiological (e.g., autonomic nervous system) behavioral (e.g., freezing, escape, fight, and avoidance), and cognitive responses (77, 78). Anxiety- and chronic pain 
symptomatology are characterized by the engagement of the of the extended amygdala structures, e.g., the bed nucleus of the stria terminalis along with allostatic 
load in the form of massive outpouring of stressogenic neurotransmitters and hormones manifested in negative affective states (10, 92).
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(e.g., low heart rate variability) (90, 91); they are derived from 
uncertain threats and/or from contextual learning of the remote 
stimuli (Table  1). In psychological terms anxiety represents a 
failure to defend against unconscious libidinal drives (66). Acute 
pain with ensuing chronicity may be likewise conceptualized to 
be the limbic system’s respective failures to gate the nociceptive 
information from reaching conscious awareness and to properly 
process such information soon thereafter (12). Furthermore, 
recurrent dopaminergic trafficking consequent to ongoing pain 
episodes gives rise to between system “anti–reward adaptations” 
(88, 92–94) recruiting CeA, NAc, BA, and BNST that in concert 
contribute to allostatic load (Figure 1) in the form of massive 
outpouring of stress hormones viz., corticotropin-releasing 
factor, epinephrine, norepinephrine, glutamate, glucocorticoids, 
and pituitary adenylate cyclase activating polypeptide (95) 
manifested in fear, anxiety, and other negative affective states 
like those arising in the context of opioid overuse, that is to say, 
“hyperkatifeia” (63, 88, 92).
PAiN AND ANXieTY: SHAReD, BUT 
SePARATe SYSTeMS CONTRiBUTiNG  
TO CHRONiFiCATiON
Amygdala and related corticolimbic regions are conventionally 
considered to be the key component of the threat processing 
system involved in the experience of fear and it is commonly 
hypothesized that they simultaneously control conscious aware-
ness of fear in conjunction with automatic defense responses 
(96). However, recent findings from human clinical (97, 98) and 
neuroimaging (99, 100) studies, as well as preclinical work (14), 
suggests that anxiety symptomatology may be attributed to a two-
system construct (Figure  2) comprised of subcortical circuits 
mediating unconscious and automatic threat-related physiologic 
and behavioral responses in conjunction with closely linked, yet 
potentially independent higher corticolimbic networks produc-
ing conscious anxiety experiences with corresponding sets of 
drives and behaviors (14, 15). Their distinctiveness is supported 
by different temporal features of anxiety cognitions vs. automatic 
events (15, 101) c.f., preponderance of cognitive experiences lack-
ing recognizable nociceptive input in chronic pain patients (102). 
The fact that conscious experiences of chronic pain (17) or of 
anxiety (103) are substantially more bothersome for patients than 
sensory percepts or defensive (re)actions potentially explains the 
relative inefficiency of analgesics that mostly target subcortical 
regions (104).
The respective contributions from the amygdala and from the 
extended amygdala to acute pain/fear and to chronic pain/anxiety 
are only modulatory and indirect (15) so that the circuits that 
are directly responsible for the subjective cognitions, valua-
tions, and experiences may function independently from the 
subcortical  limbic input. Such disintegration between cognition, 
perception, and emotions may occur due to (1) substantial 
dopaminergic surges in reward, motivation, and learning centers 
leading to “hardwired” neuroplasticity in the striato-thalamic-
frontal cortical loop, with insuring top-down dissociation from 
the subcortical activity (105, 106); and/or (2) hypofunctionality 
of the excitatory glutamatergic afferents from the amygdala–hip-
pocampus complex failing to produce bottom-up restrain of the 
striato-thalamic-frontal cortical loops (105, 107, 108).
FiGURe 2 | Schematic overview of the two-system construct underlying chronic pain and anxiety disorders. Sensory inputs of nociceptive nature may give rise to 
pain; while threatening visual, auditory, gustatory, olfactory, or tactile stimuli may bring out fear. Pain is conceptualized to be a failure of the limbic system to gate 
components of nociceptive information from reaching conscious awareness (12). In psychological terms, anxiety represents a failure to defend against unconscious 
libidinal threats (66). Chronic pain and anxiety symptoms may be attributed to a disintegration of two-system construct (15) comprised of subcortical circuits 
mediating unconscious threat-related physiologic, emotional, and behavioral responses in conjunction with linked, yet potentially independent higher corticolimbic 
network producing cognitive experiences.
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Impartments of the bottom-up striato-thalamic-frontal corti-
cal modulations may be observed in a number of neuropsychi-
atric conditions associated, such as pain (109), with heightened 
dopaminergic bursts in reward, motivation, and learning centers 
(88, 110, 111). For instance, positive symptoms of schizophrenia 
may become dissociated from the mesolimbic subcortical activ-
ity and persist notwithstanding presumably complete dopamine 
blockade by antipsychotic agents in about a quarter of psychotic 
patients (112, 113). Moreover, craving in patients addicted to 
opioids persists even in the face of fully occupied opioid receptors 
(114). This is also the case for cocaine craving in cocaine depend-
ent subjects receiving agonist substitution therapy (115). Akin to 
drug addiction (116, 117), pain and anxiety chronicity lacking 
normal sensory input may be attributable to neuroplastic changes 
that become ingrained in the corticolimbic (e.g., thalamocortical, 
thalamo-striato-cortical, and amygdalo-cortical) synapses driv-
ing compulsive thoughts and repetitious actions (118).
DiAGNOSTiC AND THeRAPeUTiC 
CONSiDeRATiONS
Psycho-diagnostic and -metric assessments may define and 
monitor cognitive neuroadaptational states, while neuroimag-
ing combined with cognitive and biochemical challenges could 
be instrumental for demonstration of subcortical emotional 
and physiological aberrations. Thus, rather than targeting pain 
along the entire biopsychosocial continuum it may be useful to 
segregate this multidimensional system into cognitive, emotional, 
and sensory domains based on the distinct underlying circuitry. 
Addressing cognitive/subjective domain separately may provide 
a sound footing for understanding its role in the therapeutic 
armamentarium for chronic pain.
While none of the professionally delivered therapies for chronic 
pain appears to be superior, generic types of cognitive-behavioral 
techniques is the commonplace practice supported by clinical 
trials (118); other methodologies include motivational interven-
tion, self-help and peer support. Suboptimal outcomes of these 
intervention call for a more personalized approach accounting 
for unique biological susceptibilities along with secondary gains 
(e.g., pain as proxy for gaining pity, appreciation, or exemption 
from routine chores and responsibilities), catastrophizing and 
other cognitive distortions and problematic decision-making 
processes.
Opioid analgesic agents improve sensory components of acute 
pain and their short term use in chronic pain (119) can amelio-
rate autonomic responses by aborting stress-induced catechola-
mines releases in part via blockade of the locus ceruleus activity 
(120, 121). These beneficial properties are, however, out-
weighed by severe side effects, including those resulting from 
opioidergic and dopaminergic stimulation with secondary 
worsening of reward and motivational deficits (109), as well as 
opioid induced endocrinopathies (e.g., hypogonadism) (122). 
Moreover, opioid analgesics providing instant pain relief (i.e., 
negative reinforcement) can become a conditioned stimulus 
eliciting future painful episodes. Opioid-induced changes in 
the mesolimbic dopaminergic pathway may underlie height-
ened incentive salience attributed to opioids or to related cues 
(i.e., drug craving) as well as the amplification of hyperkatifeia 
and of sensory pain components (63, 109). Overall, opioid 
analgesics possess advantageous therapeutic properties for 
the treatment of acute pain and for mitigation of traumatic 
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memories. These qualities explain to some extent the rise of 
opioids as the drug of choice in the pharmacopeia of chronic 
pain. However, opioids’ efficacy has been questioned by modern 
(123) research suggesting relative inefficacy of these agents in 
up to 70% of patients in pooled analyses of rigorously designed 
clinical trials (124, 125).
There are other potential psychopharmacological strate-
gies for the management of the reentrant (126) autonomous 
thalamocortical circuits (105). Anti-glutamatergic agents may 
be helpful (127) and have already been successfully used in pain 
patients (128–130). As an example, ketamine administration 
produces long-term analgesia lasting at least 3  months (131). 
The findings of neocortical/cortical glutamatergic desynchro-
nization support this sort of strategies, but more research is 
needed for understanding cortical mechanisms of chronic pain 
(132). Glutamate inhibition may be also instrumental because 
of excitatory glutamatergic neurotransmission (133) sensitiza-
tion arising in the context of stress-like anti-reward phenomena 
(92) resulting from pain-induced activation of dopaminergic 
pathways. Similar to chronic pain, PTSD’s cognitive symptoms 
of flashbacks and intrusive recollections may be temporarily 
disconnected from the anti-reward stress (27, 134) and respond 
to anti-glutamatergic agents (135). These findings add further 
support for the proposed and therapeutic strategies for chronic 
pain patients.
SUMMARY AND CONCLUSiON
Striato-thalamic-frontal cortical pathways coordinate motor, 
cognitive, and emotional functions within the brain, includ-
ing regulation of fear- and anxiety-related amygdala activity 
(136) while the limbic system represents a set of subcortical 
and cortical structures engaged (among other tasks) in the 
processing of emotions, motivation, stress, and fear (137). 
This review compares the roles played by the systems above in 
acute/chronic pain and in fear/anxiety conditions to indicate 
that some features are shared. For example, there are parallels 
in the acute harm prevention motivation typical of both acute 
pain and fear. Conspicuous similarities between chronic pain 
and anxiety include lack of survival value, involvement of the 
adrenomedullary system, autonomic responses, the key role 
of the extended amygdala, and related limbic structures in the 
emotional/physiological components and disintegration of the 
cognitive and behavioral/physiological phenomena. On the 
other hand, nociceptive, neuropathic, immune, degenerative, 
traumatic, and malignant pain sources may be associated with 
diffused tissue damage (88), which is not typical of patients with 
fear or anxiety.
Although limbic system is commonly implicated in the 
pathophysiology of chronic pain syndromes (12), here chronic 
pain is also postulated to result from dissociation of limbic 
structures from physiologically linked striato-thalamic-frontal 
cortical pathways. Prefrontal cortex, amygdala, NAc, and 
thalamic nuclei are the key information hubs (138) and their 
firing/communication impairments underlie fundamental 
psychiatric symptoms involving perception, arousal, cognition, 
and emotions (139). Accordingly, the symptoms may be derived 
from top-down or bottom-up dysfunction or combination. 
Abnormal bottom-up activity results in excessive responses to 
painful (hyperalgesia) or even normally non-painful (allodynia) 
stimuli with corresponding deficiency in reward function and 
an overwhelming urge to eradicate pain (88, 92). These may 
become disintegrated from the top–down changes manifested in 
unrealistic and even catastrophic (140) expectation of continued 
pain and/or of unsuccessful analgesia, subjective pain overvalu-
ation with regard to a subjectively acceptable amount of pain, 
i.e., framing (88).
Treatment with opioid analgesics does not adequately 
address such cognitive distortions and may even worsen them 
(109, 141). If corroborated by human studies, the abovemen-
tioned insights will have implications for the primary and 
secondary prevention of pain chronification. Identification of 
neurobiologic risk factors for chronic pain could lead to screening 
of vulnerable individuals. Those with heightened vulnerability 
owing to baseline anxiety symptomatology might be counseled 
to avoid prolonged pain exposure (primary prevention), or 
selected for early intervention (secondary prevention) even in 
the presence of mild warning signs (e.g., anxiety, drug seeking, 
and catastrophizing) early [<3 months (142)] in the course of 
the pain-related illness. The proposed model of chronic pain 
could also have treatment implications, as it supports the use of 
both psychosocial and pharmacological interventions for ame-
lioration of chronic pain problems. Clinical experience suggests 
that utilization of such combined interventions is lower (143) 
than what could be projected from positive outcomes of clinical 
trials (144). And so, this review provides clinical researches 
and practitioners alike with the important knowledge base for 
understanding the rationale for anxiolytic therapy and raises 
their awareness of the unmet psychosocial needs of chronic 
pain patients. Lastly, this model may also provide important 
leads for recognition and treatment of pain problems in patients 
with other neuropsychiatric disorders, including schizophrenia, 
addictions, and major depression (109).
It is conceivable that future therapeutic interventions targeting 
pain will address somewhat independent emotional/sensory and 
cognitive/behavioral components. Patients will be then charac-
terized according to this dichotomy and clear cut cases will be 
speared side effects by only receiving interventions aimed at the 
specific system. The time is probably ripe to commence clinical 
trials to pursue the presented ideas.
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